Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease
Category: #health  By Pankaj Singh  Date: 2019-10-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Yumanity starts Phase 1 trial of YTX-7739 to treat Parkinson’s disease

Number of cases where people are affected with neurodegenerative diseases have been growing at a substantial pace. Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases found across the world. Various biopharmaceutical firms are working to discover and develop novel therapies to minimize the impact of these diseases on human life.  

The latest contribution to this trend was done by Yumanity Therapeutics, a US based biotechnology firm focused at serving people affected with neurodegenerative diseases across the world, reportedly announced that the dosage of the first subject cohort in a Phase 1 clinical study evaluating the tolerability and safety of YTX-7739 in healthy candidates.

YTX-7739, the lead investigational treatment of Yumanity, is built to stop Stearoyl-CoA-Desaturase (SCD), a validated biologic target which recently showed potential in the field of neurodegenerative diseases by protecting the cells from a-synuclein toxicity, the foremost driver of the Parkinson’s disease.

Chief Scientific Officer at Yumanity Therapeutics, Kenneth Rhodes, Ph.D. stated that development of effective treatments for individuals suffering from devastating neurodegenerative diseases has always been a challenge since very few novel targets and hypotheses have been explored. The company advanced its SCD inhibitor YTX-7739, into clinical development due to the recent evidences found in the company.

Rhodes added that these evidences demonstrate YTX’s potential for protecting cells from a-synuclein toxicity. The company looks forward to completely characterizing potential clinical usage of YTX-7739, which is clearly different for the Parkinson’s disease treatments that are currently available, as they only mitigate the symptoms and not its underlying causes.     

The dose-escalation, placebo-controlled, double-blind, crossover trial is aimed at evaluating the tolerability, pharmacokinetics and safety of single ascending YTX-7739 doses in healthy adult volunteers.

A second trial, evaluating multiple ascending doses in the healthy adult volunteers as well as patients with Parkinson’s disease, would follow. The Phase 1 single ascending dose trial would enroll approximately 40 participants. After the completion of Phase 1 trial, the company hopes to enhance YTX-7739 into Phase 1b proof-of-concept clinical study during the last two quarters of 2020.     

Chief Executive Officer at Yumanity Therapeutics, Richard Peters, M.D., Ph.D., stated that since the company’s inception, uncovering novel targets and pathways in order to tackle significant medical issues has been the its goal.

Peters added that this phase 1 trial would provide crucial validation for a wide application of the company’s technology to further help address possibly the most crucial therapeutic challenges of the present. 

Source credit: http://www.yumanity.com/wp-content/uploads/2019/10/Yumanity_Phase-1-Trial-Initiation_Press-Release_FINAL.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
By Pankaj Singh

Genentech, Inc., a subsidiary of the Roche Group, has reportedly announced the completion of a sBLA (supplemental Biologics License Application) submission to the U.S. FDA (Food and Drug Administration) for Tecentriq ® (atezolizumab) in combinati...

FDA issues a cybersecurity warning for GE medical equipment
FDA issues a cybersecurity warning for GE medical equipment
By Pankaj Singh

The U.S. Food and Drug Administration, an agency within the U.S. Department of Health and Human Services, recently issued a safety communication informing patients, health care providers and facilities regarding the cybersecurity vulnerabilities...

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...